241 related articles for article (PubMed ID: 9500553)
1. An intramolecular SH3-domain interaction regulates c-Abl activity.
Barilá D; Superti-Furga G
Nat Genet; 1998 Mar; 18(3):280-2. PubMed ID: 9500553
[TBL] [Abstract][Full Text] [Related]
2. Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain.
Brasher BB; Roumiantsev S; Van Etten RA
Oncogene; 2001 Nov; 20(53):7744-52. PubMed ID: 11753652
[TBL] [Abstract][Full Text] [Related]
3. Introduction of a loss-of-function point mutation from the SH3 region of the Caenorhabditis elegans sem-5 gene activates the transforming ability of c-abl in vivo and abolishes binding of proline-rich ligands in vitro.
Van Etten RA; Debnath J; Zhou H; Casasnovas JM
Oncogene; 1995 May; 10(10):1977-88. PubMed ID: 7539119
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylation of c-Abl by protein kinase Pak2 regulates differential binding of ABI2 and CRK.
Jung JH; Pendergast AM; Zipfel PA; Traugh JA
Biochemistry; 2008 Jan; 47(3):1094-104. PubMed ID: 18161990
[TBL] [Abstract][Full Text] [Related]
5. Mutation of a phenylalanine conserved in SH3-containing tyrosine kinases activates the transforming ability of c-Abl.
Jackson PK; Paskind M; Baltimore D
Oncogene; 1993 Jul; 8(7):1943-56. PubMed ID: 8510937
[TBL] [Abstract][Full Text] [Related]
6. Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase.
Nagar B; Hantschel O; Seeliger M; Davies JM; Weis WI; Superti-Furga G; Kuriyan J
Mol Cell; 2006 Mar; 21(6):787-98. PubMed ID: 16543148
[TBL] [Abstract][Full Text] [Related]
7. Transactivation of Abl by the Crk II adapter protein requires a PNAY sequence in the Crk C-terminal SH3 domain.
Reichman C; Singh K; Liu Y; Singh S; Li H; Fajardo JE; Fiser A; Birge RB
Oncogene; 2005 Dec; 24(55):8187-99. PubMed ID: 16158059
[TBL] [Abstract][Full Text] [Related]
8. Crystal structure of the abl-SH3 domain complexed with a designed high-affinity peptide ligand: implications for SH3-ligand interactions.
Pisabarro MT; Serrano L; Wilmanns M
J Mol Biol; 1998 Aug; 281(3):513-21. PubMed ID: 9698566
[TBL] [Abstract][Full Text] [Related]
9. Analysis of chimeric Gag-Arg/Abl molecules indicates a distinct negative regulatory role for the Arg C-terminal domain.
Mysliwiec T; Perego R; Kruh GD
Oncogene; 1996 Feb; 12(3):631-40. PubMed ID: 8637720
[TBL] [Abstract][Full Text] [Related]
10. Modelling of the ABL and ARG proteins predicts two functionally critical regions that are natively unfolded.
Buffa P; Manzella L; Consoli ML; Messina A; Vigneri P
Proteins; 2007 Apr; 67(1):1-11. PubMed ID: 17211892
[TBL] [Abstract][Full Text] [Related]
11. RIN1 is an ABL tyrosine kinase activator and a regulator of epithelial-cell adhesion and migration.
Hu H; Bliss JM; Wang Y; Colicelli J
Curr Biol; 2005 May; 15(9):815-23. PubMed ID: 15886098
[TBL] [Abstract][Full Text] [Related]
12. Single point mutations in the SH2 domain impair the transforming potential of vav and fail to activate proto-vav.
Katzav S
Oncogene; 1993 Jul; 8(7):1757-63. PubMed ID: 8510922
[TBL] [Abstract][Full Text] [Related]
13. Mutagenic analysis of Vav reveals that an intact SH3 domain is required for transformation.
Groysman M; Nagano M; Shaanan B; Katzav S
Oncogene; 1998 Sep; 17(12):1597-606. PubMed ID: 9794237
[TBL] [Abstract][Full Text] [Related]
14. Analysis of human c-Abl tyrosine kinase activity and regulation in S. pombe.
Walkenhorst J; Goga A; Witte ON; Superti-Furga G
Oncogene; 1996 Apr; 12(7):1513-20. PubMed ID: 8622867
[TBL] [Abstract][Full Text] [Related]
15. Critical amino acid substitutions in the Src SH3 domain that convert c-Src to be oncogenic.
Miyazaki K; Senga T; Matsuda S; Tanaka M; Machida K; Takenouchi Y; Nimura Y; Hamaguchi M
Biochem Biophys Res Commun; 1999 Oct; 263(3):759-64. PubMed ID: 10512753
[TBL] [Abstract][Full Text] [Related]
16. Intrinsic regulation of the interactions between the SH3 domain of p85 subunit of phosphatidylinositol-3 kinase and the protein network of BCR/ABL oncogenic tyrosine kinase.
Ren SY; Xue F; Feng J; Skorski T
Exp Hematol; 2005 Oct; 33(10):1222-8. PubMed ID: 16219545
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of two novel SH2 domain-containing proteins from a yeast two hybrid screen with the ABL tyrosine kinase.
Oda T; Kujovich J; Reis M; Newman B; Druker BJ
Oncogene; 1997 Sep; 15(11):1255-62. PubMed ID: 9315092
[TBL] [Abstract][Full Text] [Related]
18. Crosstalk between the catalytic and regulatory domains allows bidirectional regulation of Src.
Gonfloni S; Weijland A; Kretzschmar J; Superti-Furga G
Nat Struct Biol; 2000 Apr; 7(4):281-6. PubMed ID: 10742171
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the activity of SRC and Abl tyrosine protein kinases by the binding of the Wiskott-Aldrich syndrome protein.
Schulte RJ; Sefton BM
Biochemistry; 2003 Aug; 42(31):9424-30. PubMed ID: 12899629
[TBL] [Abstract][Full Text] [Related]
20. Role of the Brk SH3 domain in substrate recognition.
Qiu H; Miller WT
Oncogene; 2004 Mar; 23(12):2216-23. PubMed ID: 14676834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
